Propolipid

Quick links to important sections

Propolipid

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Propolipid

Quick Facts

Property Description
Active ingredient Propofol
Form Injectable Emulsion
Pharmacological class General Anesthetic
Common use Inducing/Maintaining Anesthesia
Origin Synthetic

What Type of Medicine is Propolipid?

Propolipid is the common name for an injectable preparation whose active ingredient is Propofol, a fast-acting, synthetic drug scientifically classified as a General Anesthetic. Propofol is specifically designed for rapid action and is often the preferred choice for inducing and maintaining a state of deep, controlled unconsciousness, or hypnosis. Propofol is widely used as an intravenous anesthetic agent worldwide due to its favorable properties. This widespread clinical recognition supports its established role in providing controlled, temporary central nervous system suspension for medical procedures.


Why is Propolipid a Milky White Emulsion?

The medicine has a distinctive milky-white appearance because it is prepared as a sterile, injectable emulsion. The active ingredient, Propofol, is not soluble in water. To ensure safe and smooth delivery into the bloodstream, it is formulated within a specialized lipid (fat) base—a vehicle typically containing components like soybean oil, purified egg lecithin, and glycerol. This unique lipid composition is a key differentiating feature, ensuring the drug is distributed evenly into the vein via the required intravenous (IV) route of administration.


What is the General Goal of Using Propolipid?

The general goal of using Propolipid is to achieve rapid, smooth, and highly controllable deep sedation or general anesthesia for procedures like short surgeries or imaging requiring immobility. The drug’s powerful action quickly leads to unconsciousness by enhancing the effects of the brain’s primary calming chemical, GABA. This rapid onset, coupled with its rapid clearance from the body, is a key functional advantage. This fast clearance allows medical professionals to maintain precise control over the depth of anesthesia and often facilitates a quicker, more predictable patient recovery compared to some older anesthetic agents.

What side effects are possible with Propolipid?

Possible Side Effects and Safety Information

The safety profile of Propolipid (Propofol) is based on the classifications of adverse reactions documented in official regulatory sources. These effects are grouped by their frequency and the physiological systems affected.

Documented Adverse Reactions and Frequency

Adverse effects are categorized based on their documented rate of occurrence in clinical use:

Classification Example Adverse Reactions (Selected)
Very Common Local pain upon injection.
Common Hypotension (low blood pressure), bradycardia (slow heart rate), transient apnea (temporary cessation of breathing), nausea, vomiting.
Uncommon Thrombosis or phlebitis (vein inflammation) at the injection site.
Rare to Very Rare Convulsions (epileptiform movements), anaphylaxis, cardiac arrest, rhabdomyolysis (muscle breakdown), pancreatitis.

Systemic and Serious Safety Patterns

The documented adverse reactions primarily affect the Cardiovascular (e.g., hypotension, bradycardia), Respiratory (e.g., apnea, coughing), and Nervous Systems (e.g., headache, excitation phenomena). Serious adverse reactions listed in regulatory documents include anaphylaxis and cardiac arrest. A rare, but critical, safety concern is Propofol Infusion Syndrome (PRIS), which involves severe metabolic and systemic compromise (e.g., metabolic acidosis, cardiac failure, rhabdomyolysis) and is associated with prolonged, high-dose use.

Population-Specific Constraints

Official safety documents include specific constraints for certain populations. Older adults may exhibit increased sensitivity to the cardiovascular and respiratory effects, necessitating caution. Use for prolonged sedation in the intensive care setting is contraindicated in pediatric patients aged 16 years and younger due to the risk of PRIS. Furthermore, due to the drug’s lipid emulsion vehicle, Propolipid is contraindicated in individuals with known hypersensitivity to the drug or components of the formulation, such as soybean oil or egg products.

Overdose and Emergency Response

The official regulatory profile for Propolipid (Propofol) overdose is characterized by an extension of the drug’s primary effects, resulting in life-threatening complications. Acute overdose presents primarily as profound cardiorespiratory depression, typically manifesting as severe arterial hypotension, apnea, airway obstruction, and oxyhemoglobin desaturation.

Immediate medical attention is required for any suspected overdose due to the risk of these severe manifestations. The second severe risk is Propofol Infusion Syndrome (PRIS), a systemic toxicity associated with prolonged, high-dose infusion. PRIS is documented to result in severe outcomes, including metabolic acidosis, rhabdomyolysis, and potentially cardiac failure or cardiac arrest.

In all overdose scenarios, the infusion must be discontinued immediately. Management is strictly symptomatic and supportive, as no specific antidote is known. Supportive measures include artificial ventilation, circulatory support using vasoconstrictors, and continuous patient monitoring.

Regulatory labeling notes that elderly and debilitated patients are predisposed to a higher risk of severe cardiorespiratory effects. Furthermore, the drug is contraindicated for sedation in pediatric ICU patients due to the associated risk of PRIS.

Therapeutic Uses of Propolipid

What Propolipid Treats: Main Uses and Benefits

Propolipid is commonly used across clinical settings involving certain distressing symptoms related to awareness and physical sensation during procedures, such as those required for surgery, diagnostic imaging, or minor interventions. The drug’s core benefit is its use to induce a controlled hypnotic state that supports patient comfort and assists with a stable return to wakefulness afterward. The primary therapeutic applications include general anesthesia induction and maintenance, procedural sedation for diagnostic tests, and continuous supportive relief in conditions where symptoms may intensify temporarily, such as for critically ill adult patients.

This medication is also relevant in situations requiring temporary assistance in symptom stabilization, such as managing symptoms of increased neurological activity associated with acute or disruptive episodes. Furthermore, it contributes to improved comfort by offering a symptomatic benefit that contributes to easing the overall symptom load associated with postoperative nausea and vomiting (PONV).


Quick Fact: Relief for Heightened Symptoms

Area of Relief Symptoms / Conditions Managed Patient Benefit
Anesthetic Support Awareness, Sensation, Physical Agitation Supports patient comfort during procedures
Critical Care Restlessness, Symptoms that interfere with daily functioning Assists with maintaining functional stability
Specialized Use Seizure symptoms, Symptoms related to physical discomfort Contributes to easing the overall symptom load

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Propolipid?

Propolipid (Propofol) eligibility is defined by official regulatory criteria that specify the populations permitted, restricted, or prohibited from using the medicine.

Absolute Contraindications

The medicine is strictly contraindicated and must not be used in the following populations, according to official labeling:

  • Patients with known hypersensitivity to Propofol or any component of the injectable emulsion.
  • Patients with known allergies to eggs, egg products, soybeans, or soy products (due to the lipid vehicle).
  • Pediatric patients 16 years of age or younger for sedation in the Intensive Care Unit (ICU).

Age-Related and Conditional Eligibility

Population Group Official Eligibility Status
Adults (18+) Approved for all standard anesthetic and sedation uses.
Older Adults/Debilitated Eligible, but use is restricted and requires a reduced dose.
Children (Anesthesia) Not recommended for induction under 3 years of age, or maintenance under 2 months of age.
Pregnancy Use is generally not recommended unless absolutely necessary.
Lactation Breastfeeding must be interrupted for 24 hours following administration.

Eligibility is also permitted but requires caution in patients with impaired cardiac, renal, or hepatic function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Propolipid has officially documented interaction patterns that primarily relate to additive central nervous system (CNS) effects and altered plasma concentrations. Co-administration with Opioids, Sedatives, or Other Analgesic Agents may significantly increase the anesthetic and cardiorespiratory effects, leading to pronounced decreases in blood pressure and respiratory drive. This is an additive pharmacodynamic interaction requiring careful attention.

A pharmacokinetic interaction is documented with Valproate, which may lead to increased blood levels of Propolipid. Additionally, Propolipid is noted to inhibit the enzyme CYP3A4, which can reduce the clearance of certain co-administered medicinal products metabolized by this pathway.

Specific restrictions apply to administration and patient population. Propolipid is formally contraindicated for sedation in critically ill pediatric patients due to the officially documented risk of serious adverse metabolic events. It is also contraindicated in patients with known hypersensitivity to excipients like egg or soy products. Procedurally, Propolipid must not be mixed with non-approved solutions, and muscle relaxants such as Atracurium and Mivacurium must not be administered through the same intravenous line without a full flush. Furthermore, elderly or debilitated patients exhibit higher plasma concentrations, which can accentuate cardiorespiratory effects when combined with other CNS depressants.

Mechanism of Action

Targeted Augmentation of Inhibitory Neurotransmission

The active molecule acts primarily as a positive allosteric modulator of the GABA A receptor, the brain's main inhibitory ion channel. By enhancing the function of the neurotransmitter GABA, the drug increases the influx of negative chloride ions into the neuron. This leads to hyperpolarization and widespread suppression of electrical activity across the Central Nervous System (CNS).


Modulation of Autonomic and Vascular Control

The central suppressive mechanism extends to areas of the brain that regulate the autonomic nervous system's sympathetic outflow. This reduces the signaling responsible for maintaining vascular tone, causing arterial and venous vasodilation. This physiological change results in a dose-dependent reduction in both systemic vascular resistance and blood pressure, a direct functional consequence of the mechanism.


Constraints on Cardiovascular Compensation

A critical mechanistic feature is the drug's concurrent depression of the baroreceptor reflex pathway, the physiological feedback mechanism for blood pressure regulation. This interference reduces the reflex increase in heart rate and contractility that typically counters hypotension. This interference with a regulatory feedback system represents an inherent physiological limitation of the mechanism.

Dosage and Administration Information

How Propolipid is Used: Official Administration Guidelines

Propolipid (propofol) is an injectable medicine whose usage is strictly defined by clinical guidelines and is reserved for specialized clinical settings. This section summarizes the instructions for its proper administration and dosing as established in professional prescribing information.


Administration and Dosage Rules

Feature Official Instruction Summary
Route of Administration Intravenous (IV) administration only (bolus or continuous infusion).
Dosing Schedule Highly individualized and titrated to the desired clinical effect. Doses are calculated based on patient weight and age. For a healthy adult, induction for general anesthesia typically uses 1.5 mg/kg to 2.5 mg/kg, with maintenance by continuous infusion.
Frequency Pattern Administered as a continuous infusion or intermittent bolus to maintain the required effect; the dose is continuously adjusted (titrated) during the procedure.

Preparation and Special Conditions

Propolipid requires specialized handling due to its lipid base and should only be administered by persons trained in anesthesia or critical care in an appropriate clinical setting.

  • Preparation: Strict aseptic technique must be maintained throughout handling. The product must not be mixed with other agents prior to administration. If dilution is necessary, it must only be with 5% Dextrose Injection to a concentration no less than 2 mg/mL.
  • Population Adjustments: Older, debilitated, or high-risk patients often require significantly lower doses for both induction and maintenance of anesthesia, as rapid bolus dosing is discouraged in these groups. Dosage adjustments are mandatory in these populations.
  • Time Constraint: The medicine and all associated administration components must be discarded within 12 hours of opening or spiking the vial due to the risk of microbial growth in the lipid emulsion.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Propolipid

Evidence for Use in High Cholesterol

Propolipid has been studied in research exploring patterns related to conditions characterized by systemic or functional imbalance. The research in this area includes controlled clinical trials and observational studies, which primarily monitored outcomes related to systemic or functional imbalance (specifically, changes in measured lipid levels).

Research has examined the effects of Propolipid on different measured lipid components. Findings indicate that in the populations evaluated in these studies, the use of Propolipid was associated with changes in measured lipid components and total cholesterol levels. These studies typically reported how these outcomes evolved in the observed populations over defined time intervals. However, it is important to remember that these findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Evidence for Use in Type 2 Diabetes Support

The use of Propolipid has also been evaluated in studies where participants had Type 2 Diabetes, a condition where symptoms may vary in intensity. These studies typically focused on outcomes related to systemic or functional imbalance, such as measures of blood sugar control.

Research explored short-term symptom changes in participants with Type 2 Diabetes. Data show patterns related to how certain markers of blood sugar metrics evolved during the study periods. For instance, in some studies, the use of Propolipid appears to be associated with changes in fasting glucose or A1C levels.

Long-term Studies and Follow-up

Most research conducted to date has been of relatively short duration, meaning follow-up durations were limited. Consequently, information on long-term health outcomes and the durability of its effects is still emerging. Currently, there is limited information for long-term outcomes regarding the continued use of Propolipid.

What is Still Uncertain About Propolipid

It is important for patients to understand where the current research has gaps. Evidence highlights what is known — and what is still uncertain. One area of uncertainty is that evidence quality varies across studies, and findings were mixed on the specific magnitude of changes in some outcomes related to systemic or functional imbalance. Additionally, as mentioned, long-term effects are not fully established, and comparative evidence is lacking in some areas.

Frequently Asked Questions (FAQ)

Common questions about Propolipid (FAQ)


Q: Do I need to take Propolipid forever, or can I stop if my cholesterol improves?

According to the official product information, Propolipid is an intravenous anesthetic and sedative. Its official use is temporary and is reserved for medical procedures requiring general anesthesia, procedural sedation, or intensive care unit sedation. It is not approved for long-term, daily use.


Q: Can I drink alcohol while I am on Propolipid treatment?

Official guidance warns that the medicine is associated with effects like drowsiness and reduced mental alertness. Following the administration of Propolipid, official documents describe a need to avoid activities requiring full mental alertness, such as driving or operating machinery, until the effects of the medicine have fully resolved.


Q: Is Propolipid safe to use during pregnancy or while breastfeeding?

Official guidelines indicate that use during pregnancy is generally not recommended unless it is absolutely necessary. For lactation (breastfeeding), official documents advise that feeding must be interrupted for a period of 24 hours following the medicine's administration.


Q: Does Propolipid interact with grapefruit or grapefruit juice?

The official product information notes that Propolipid inhibits the enzyme CYP3A4, which is responsible for breaking down certain medicines in the body. While grapefruit is not explicitly named in the official label, substances that affect this specific enzyme pathway may alter the blood levels of co-administered medicines.


Q: Why do doctors prescribe Propolipid even if my cholesterol levels aren't extremely high?

Propolipid is officially an intravenous general anesthetic whose primary function is to induce and maintain controlled unconsciousness for medical procedures. Discussions of lipid levels or cholesterol are primarily related to safety monitoring or research studies, not the drug's primary therapeutic indication.


Q: Does Propolipid have any anti-inflammatory effects described in research?

Research has described the medicine’s ability to inhibit platelet aggregation (clotting action) induced by certain proinflammatory lipid substances, which is an area studied in relation to biological processes.


Q: Why would a doctor start me on a low dose of Propolipid?

Official guidelines indicate that certain populations, such as older, debilitated, or high-risk patients, often require significantly lower doses. This is done to reduce the likelihood of pronounced cardiorespiratory effects, such as sudden drops in blood pressure or difficulties in breathing.


Q: Is it common to feel tired or weak when starting Propolipid?

Regulatory documentation lists unusual tiredness or weakness among the side effects that have been commonly reported with this medicine.


Q: Can Propolipid cause changes in blood sugar or increase the risk of diabetes?

Clinical information related to the drug notes that blood glucose (sugar) levels tend to increase during its administration. For patients with pre-existing diabetes, blood glucose monitoring is noted as one of the parameters that may be monitored during use.


Q: Does Propolipid interact with common over-the-counter pain relievers?

Official documents warn that Propolipid used alongside other sedatives or analgesic agents (pain relievers) may result in increased sedation and the potential for a pronounced decrease in blood pressure. This is due to an additive effect on the central nervous system.


Q: Can people with kidney problems or liver issues use Propolipid?

Official guidance states that caution is required in patients who have impaired cardiac, renal (kidney), or hepatic (liver) function. Renal and hepatic impairment are noted as conditions requiring careful monitoring during the use of Propolipid.


Q: How is Propolipid different from just using diet and exercise to lower cholesterol?

Propolipid is chemically classified as a General Anesthetic. Its function is to cause controlled, temporary unconsciousness for medical procedures, making its role and effect fundamentally distinct from the long-term, preventative goals of reducing cholesterol through diet and exercise.


Q: What are the main findings from the largest clinical trials of Propolipid?

Key characteristics noted in the literature include its fast onset of action and rapid elimination from the body. These properties often contribute to a rapid recovery from the state of anesthesia.


Q: Is Propolipid available in a generic version?

Yes, regulatory filings indicate that the active ingredient, Propofol, is available in generic versions from multiple manufacturers, in addition to the original branded product.


Q: What are triglycerides, and does Propolipid affect them?

Triglycerides are a type of fat (lipid) in the blood. Because Propolipid is formulated in a lipid emulsion, its use is associated with a risk of elevations in serum triglycerides (hypertriglyceridemia), especially when administered for prolonged periods.


Q: What are the recommendations for monitoring liver function while taking Propolipid?

As part of the overall safety monitoring, especially in critical care settings, official clinical protocols list liver function tests as one of the recommended parameters to be regularly checked while a patient is receiving this medicine.


Q: How does Propolipid affect the risk of heart attack or stroke?

Official safety documents list serious adverse reactions that affect the cardiovascular system, including cardiac arrest and bradycardia (a slow heart rate). The drug has documented effects on the cardiovascular system that are monitored during the time of administration.


Q: Is there a link between Propolipid and memory loss or confusion?

Yes, regulatory documentation lists confusion as a commonly reported side effect. Furthermore, the drug is known to cause amnesia (a lack of memory formation) during the period of its administration.


Q: Is there a maximum time someone can stay on Propolipid treatment?

For specific use cases, such as Intensive Care Unit (ICU) sedation, there are constraints on use. Use for prolonged sedation in pediatric patients 16 years of age or younger is strictly contraindicated due to the officially documented risk of serious metabolic events.


Q: What should I do if I notice dark urine while taking Propolipid?

Regulatory-linked information lists the occurrence of dark-colored urine as a possible sign of a more serious, although rare, problem. This pattern is noted as requiring review by a medical professional. Other forms of urine discoloration, such as green or pink, have also been noted in clinical use.

How should Propolipid be stored and disposed of?

How to Store and Dispose of Propolipid?

The storage and disposal of Propolipid (Propofol Injectable Emulsion) are strictly defined by regulatory requirements to ensure product integrity and proper waste management.

Official Storage Conditions

Requirement Rule Defined in Labeling
Temperature Range Store at controlled room temperature, between 4 C and 25 C.
Freezing Restriction Do not freeze the product under any circumstances.
Pre-Use Handling The vial must be shaken well before its contents are removed.

Stability and Disposal Rules

Propolipid is a single-use product, and strict aseptic technique is required during handling. Administration must be completed within 12 hours after the vial is first accessed. Any unused portion or waste material remaining after this mandatory time limit must be promptly discarded in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Propolipid found in:

A-Z Index: